drugset / Trial / NCT00469183

Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

NCT00469183

Phase 4 Completed 70 enrolled Galderma R&D
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Evaluate atrophogenic potential of long-term use of Tri-Luma Cream on facial Melasma through biopsy examination.

Timeline

Start
2006-05
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroquinone Small molecule 4 % Topical
Subject Tretinoin Small molecule 0.05 % Topical
Subject fluocinolone acetonide Small molecule 0.1 % Topical